ARTLEGIA

Class [005]
Pharmaceutical preparations and substances for the treatment of neurology and immunology diseases and disorders, namely, a pathological disorder being an arthritis, rheumatoid arthritis, psoriatic arthritis, systemic onset juvenile idiopathic arthritis, juvenile idiopathic arthritis, juvenile psoriatic arthritis, systemic lupus erythematosus (SLE), mixed connective tissue disease, connective tissue disorder, scleroderma, ankylosing spondylitis, dermatomyositis, polymiositis, Sjogren's syndrome, psoriasis, asthma, Crohn's disease, ulcerative colitis, autoimmune colitis, amyloidosis, uveitis, autoimmune uveitis, immune-mediated uveitis, coeliac disease, vasculitis, stroke, type I diabetes mellitus, immune-mediated lung disease, immune-mediated encephalitis, meningoencephalitis, nervous system autoimmune disorders, Alzheimer's Disease, immune-mediated and autoimmune pancreatitis, transplant rejections (including graft versus host disease), cerebral atherosclerosis, acute respiratory distress syndrome (ARDS) associated with moderate to severe coronavirus disease 2019 (COVID-19), cytokine release syndrome (CRS) associated with moderate to severe coronavirus disease 2019 (COVID-19).